BioCentury
ARTICLE | Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

November 14, 2018 11:32 PM UTC

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Wednesday decision that invalidated second medical use patent claims for Lyrica pregabalin from Pfizer Inc. (NYSE:PFE) on the grounds of insufficiency.

The ruling reiterates that "plausibility is a requirement for sufficiency" in U.K. courts, according to Jennifer O'Farrell, a partner in the biotechnology and life sciences group at IP firm Boult Wade Tennant...